BioTech 365
SEPTEMBER 2, 2020
Ready-to-use kit enables rapid adeno-associated virus (AAV) titer determinations during the manufacture of AAV vectors UPPSALA, Sweden–(BUSINESS WIRE)–Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and a leading provider of peptide synthesizers and reagents, today announced the introduction … Continue (..)
Drug Discovery World
SEPTEMBER 25, 2023
CRISPR gene editing companies Integrated DNA Technologies (IDT) and Aldevron have inked a new global distribution agreement to expand CRISPR products for cell and gene therapy customers. The post Partners working to realise the future of genomic medicine appeared first on Drug Discovery World (DDW).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Roots Analysis
JUNE 1, 2022
Recent technological advancements have led to development of novel DNA cloning kits and reagents, which are cost-effective, faster and more efficient than conventional methods. DNA Cloning Reagent Providers – Current Market Landscape. DNA Cloning Reagents Market. DNA Cloning Kit Providers – Current Market Landscape.
Drug Discovery World
APRIL 3, 2023
As the industry’s awareness of alternatives to traditional antibodies continues to grow, there is increasing demand for these alternatives, which we are seeing particularly within the therapeutic sector, to enable targeted therapeutics and enable the emerging gene therapy market. DS: The company now has clients across big pharma.
The Pharma Data
OCTOBER 14, 2020
15, 2020 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH), a leading provider of proteins, antibodies and cytokines today announced that its Woburn, Massachusetts site received ISO 13485:2016 certification for Medical Device and Quality Management Systems. MINNEAPOLIS , Oct. ” About Bio-Techne Corporation (NASDAQ: TECH).
Drug Discovery World
MARCH 13, 2023
The cell and gene therapy (CGT) landscape has grown significantly in the past year. Between the 24 therapies already approved by the FDA 1 and a marked increase in clinical trials, widespread accessibility to precision medicine feels within reach. But this kind of change can’t happen in a bubble.
Drug Discovery World
OCTOBER 13, 2022
There was a selection of the technologies we will present including cell-based assays, ion indicator dyes, inhibitors, pharmacokinetic assays, bioisimilars, assay development antibodies, conjugation particles and other reagents for your drug discovery and development pipeline. . Looking forward .
Expert insights. Personalized for you.
52 
Let's personalize your content